Trial Profile
Examination of the efficacy of dapagliflozin in patients with type 2 diabetes
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 28 Oct 2022 Planned End Date changed from 31 Mar 2020 to 31 Dec 2025.
- 28 Oct 2016 Status changed from not yet recruiting to recruiting.
- 14 May 2016 New trial record